Wed, Sep 17, 2014, 3:10 PM EDT - U.S. Markets close in 50 mins.


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • blehair Jun 24, 2013 12:04 PM Flag

    Why +FEV1% improvements shown from inhaler trials are quite significant...

    CF lung function deteriorates continuously. FEV1 normal function is more than 80%, while severe cases are less than 40%, and transplant qualifications are met at 20%.

    The simple fact for CF sufferers is that it ends with death or transplants because lung function becomes too poor.

    Considering placebo arms consistently perform at 0% or lower +FEV1% improvement levels illustrates how significant even 1% superiority in an inhaler arm can be for sufferers. That could perpetually stave off the less than 25% FEV1% level from being hit years, even more than a decade.

    That's why TOBI, despite it's relatively bad efficacy now, will continue to rack in excess of $400M.

    Don't undervalue the impact that these inhalers have, even if it's a few percentages.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
13.45+0.20(+1.51%)3:07 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.